Pyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales Agreement
PYXIS ONCOLOGY, INC.Common StockThis Supplement No. 1 to Prospectus Supplement (this "Supplement") supplements and amends the Prospectus Supplement dated November 26, 2025 (the "Prospectus Supplement").
Share
Why It Matters
Pyxis Oncology stopped a plan to sell $150 million in new shares. They had not sold any yet, so this plan is now closed.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.